Equities

Scilex Holding Co

SCLX:NAQ

Scilex Holding Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8803
  • Today's Change-0.096 / -9.81%
  • Shares traded3.84m
  • 1 Year change-33.81%
  • Beta1.0997
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3.922.184.34
Total Receivables, Net352114
Total Inventory4.211.382.56
Prepaid expenses4.054.811.84
Other current assets, total------
Total current assets473023
Property, plant & equipment, net3.671.902.11
Goodwill, net131313
Intangibles, net364139
Long term investments------
Note receivable - long term------
Other long term assets0.900.940.54
Total assets1018778
LIABILITIES
Accounts payable418.454.28
Accrued expenses1013615
Notes payable/short-term debt108020
Current portion long-term debt/capital leases--038
Other current liabilities, total0.490.2693
Total current liabilities25045169
Total long term debt17096
Total debt1250153
Deferred income tax------
Minority interest------
Other liabilities, total6.835.4537
Total liabilities27450302
SHAREHOLDERS EQUITY
Common stock0.020.010.01
Additional paid-in capital408412129
Retained earnings (accumulated deficit)(490)(376)(353)
Treasury stock - common(91)----
Unrealized gain (loss)------
Other equity, total------
Total equity(173)36(224)
Total liabilities & shareholders' equity1018778
Total common shares outstanding100141141
Treasury shares - common primary issue6000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.